No profile data available.
Alkermes plc (ALKS) is a healthcare company in the brain and nerve treatment drugs industry, based in Dublin, Ireland, with about 2,050 full-time employees.
It reported revenue of $1.48 billion for fiscal year 2025, down 5.2% from fiscal year 2024, and net income of $241.66 million. United States was its largest region in fiscal year 2025, with 93% of revenue. Its market capitalization was $6.81 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Alkermes reported $1.48 billion in revenue for fiscal year 2025, down 5.2% from $1.56 billion in fiscal year 2024.
United States: 93% of revenue by region in fiscal year 2025, followed by Rest of World (7%).
$6.81 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Jazz Pharmaceuticals plc (JAZZ), Axsome Therapeutics, Inc. (AXSM), Praxis Precision Medicines, Inc. (PRAX), PTC Therapeutics, Inc. (PTCT).